4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2024)

4D Molecular Therapeutics (FDMT) has reported Other financing activities for 5 consecutive years, with $3.1 million the latest figure, recorded in Q1 2024.

• In Q1 2024, Other financing activities rose 119.84% year-over-year to $3.1 million; the TTM figure through Mar 2024 stood at $4.6 million (up 64.58% YoY), while the FY2021 annual figure was $433000.0, changed N/A from the prior year.
• Other financing activities rose to $3.1 million in Q1 2024 per FDMT's latest filing, from -$758000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $3.1 million in Q1 2024 and bottomed at -$758000.0 in Q2 2023.
• Historically, Other financing activities has averaged $740428.6 across 5 years, with a median of $433000.0 in 2021.
• Annual changes were most pronounced in 2021 — Other financing activities surged 1880.0% — and 2023, when it soared 61.83%.
• 4D Molecular Therapeutics' Other financing activities stood at $5000.0 in 2020, then soared by 8560.0% to $433000.0 in 2021, then jumped by 102.08% to $875000.0 in 2022, then tumbled by 186.63% to -$758000.0 in 2023, then jumped by 510.69% to $3.1 million in 2024.
• Business Quant data shows FDMT's Other financing activities at $3.1 million in Q1 2024, -$758000.0 in Q2 2023, and $1.4 million in Q1 2023.